Elias, E., Oketola, A., Krishnan, S., Singh, H., Targownik, L., & Bernstein, C. N. (2019). A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE. J Can Assoc Gastroenterol.

Elias, E., A. Oketola, S. Krishnan, H. Singh, L. Targownik, and C N. Bernstein. "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE." J Can Assoc Gastroenterol 2019.

Elias, E., et al. "A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE." J Can Assoc Gastroenterol 2019.